Glaucoma Treatment Market (By Indication: Open Angle Glaucoma, Angle Closure Glaucoma, Others; By Drug Class: Prostaglandin Analogs, Beta Blockers, Alpha Agonist, Carbonic Anhydrase Inhibitors, Others; By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Glaucoma Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Glaucoma Treatment Market, by Indication, 2024-2033
8.1.1 Open Angle Glaucoma
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Angle Closure Glaucoma
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2021-2033)
9.1. Glaucoma Treatment Market, by Drug Class, 2024-2033
9.1.1. Prostaglandin Analogs
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Beta Blockers
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Alpha Agonist
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Carbonic Anhydrase Inhibitors
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2033)
10.1. Glaucoma Treatment Market, by Distribution, 2024-2033
10.1.1. Hospital Pharmacy
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Retail Pharmacy
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Online Pharmacy
10.1.3.1. Market Revenue and Forecast (2021-2033)
11.1. North America
11.1.1. Market Revenue and Forecast, by Indication (2021-2033)
11.1.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.1.3. Market Revenue and Forecast, by Distribution (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Indication (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.1.4.3. Market Revenue and Forecast, by Distribution (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Indication (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.1.5.3. Market Revenue and Forecast, by Distribution (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Indication (2021-2033)
11.2.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.3. Market Revenue and Forecast, by Distribution (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Indication (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.4.3. Market Revenue and Forecast, by Distribution (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Indication (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.5.3. Market Revenue and Forecast, by Distribution (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Indication (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.6.3. Market Revenue and Forecast, by Distribution (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Indication (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.2.7.3. Market Revenue and Forecast, by Distribution (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Indication (2021-2033)
11.3.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.3. Market Revenue and Forecast, by Distribution (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Indication (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.4.3. Market Revenue and Forecast, by Distribution (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Indication (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.5.3. Market Revenue and Forecast, by Distribution (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Indication (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.6.3. Market Revenue and Forecast, by Distribution (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Indication (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.3.7.3. Market Revenue and Forecast, by Distribution (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Indication (2021-2033)
11.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.3. Market Revenue and Forecast, by Distribution (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Indication (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.4.3. Market Revenue and Forecast, by Distribution (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Indication (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.5.3. Market Revenue and Forecast, by Distribution (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Indication (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.6.3. Market Revenue and Forecast, by Distribution (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Indication (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.4.7.3. Market Revenue and Forecast, by Distribution (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Indication (2021-2033)
11.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.5.3. Market Revenue and Forecast, by Distribution (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Indication (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.5.4.3. Market Revenue and Forecast, by Distribution (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Indication (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
11.5.5.3. Market Revenue and Forecast, by Distribution (2021-2033)
12.1. AERIE Pharmaceuticals, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Cipla Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Akorn Operating Company LLC
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. AbbVie
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bausch & Lomb Incorporated
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Inoteck Pharmaceuticals
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Merck & Co., Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Novartis AG
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Pfizer Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Santen Pharmaceutical Co., Ltd.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample